“These Phase 3 findings demonstrate that andexanet alfa can rapidly reverse anticoagulant activity for a short or sustained period of time and that anticoagulant activity can be reinitiated following discontinuation of the infusion. The full data set was presented today in a Late-Breaking Clinical Trial oral session at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in Toronto. No subjects discontinued the study due to an adverse event. Mild infusion reactions were reported in six subjects: four in the andexanet arm and two in the placebo arm. Andexanet alfa was well tolerated, with no serious adverse events, thrombotic events, or antibodies to Factor X or Xa reported. Andexanet alfa significantly reduced the level of free unbound Eliquis in the plasma and restored thrombin generation to normal. Andexanet alfa produced rapid reversal of the anticoagulant effect of Eliquis, as measured by anti-Factor Xa activity, which was sustained for the duration of the infusion. This second part of the study achieved all primary and pre-specified secondary endpoints with high statistical significance. Food and Drug Administration (FDA)-designated breakthrough therapy, administered as an intravenous (IV) bolus followed by a continuous two-hour infusion to sustain the reversal of anticoagulation activity of the Factor Xa inhibitor Eliquis (apixaban) in healthy volunteers ages 50-75 years. This registration-enabling study evaluated the safety and efficacy of andexanet alfa, an investigational antidote and U.S. (NYSE: PFE) today announced full results from the second part of the Phase 3 ANNEXA™-A ( Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of F Xa Inhibitors – Apixaban) study. Portola Pharmaceuticals (NASDAQ: PTLA), Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress Data Presented Today in Late-Breaking Clinical Trial Oral Session at
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |